This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
1. Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma2. Biology and Pathology of B-cell lymphoma 3. Resistance to Y-90 Ibritumomab Tiuxetan Therapy4. Features of Ibritumomab as Radionuclide Therapy5. Radiological Evaluation of Response and Resistance of Ibritumomab6. Characteristics of Ibritumomab as Radionuclide Therapy Agent7. Resistance and Heterogeneity of Intratumoral Antibody Distribution8. Radiation Dosimetry in Ibritumomab Therapy9. Combining RAIT and immune-based therapies to overcome resistance in cancer?10. Prospects for enhancing efficacy of radioimmunotherapyIndex